GE HealthCare Technologies Inc. GEHC and the University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging recently announced the launch of a Care Innovation Hub, a joint research collaboration.

The collaboration aims to address meaningful clinical challenges in three key areas — accessibility to advanced medical imaging, non-invasive diagnosis and management of neurological and neurodegenerative disease and precision oncology.

Likely Trend of GEHC Stock Following the News

Following the announcement, shares of the company moved north 4.4% to $87.34 on Tuesday. In the past six months, GEHC shares have gained 8% compared with the industry’s 11.9% growth. The S&P 500 increased 9.3% in the same time frame.

The partnership between GE HealthCare and  UCSF to establish the Care Innovation Hub positions GEHC as a leader in advanced medical imaging and precision healthcare. By focusing on automated imaging, neurodegenerative disease research, and accessible oncology solutions, GEHC aims to address critical healthcare challenges while creating opportunities for new products and revenue streams. This collaboration enhances GEHC's R&D capabilities, aligns with global healthcare demands, and strengthens its market differentiation, potentially driving long-term growth and investor confidence in the company's stock.

Meanwhile, GEHC currently has a market capitalization of $38.72 billion. In the last reported quarter, GEHC delivered an earnings surprise of 7.55%.

Image Source: Zacks Investment Research

Details on the GEHC & UCSF Collaborated Care Innovation Hub

The Care Innovation Hub focuses on building an imaging service line of the future to transform diagnostic precision and efficiency. This initiative aims to develop automated imaging techniques, such as patient-specific magnetic resonance imaging (MRI) technologies, that enable faster, more accurate, and highly personalized imaging services. By integrating artificial intelligence (AI) and machine learning, these advancements are designed to improve diagnostic workflows, reduce the time needed for imaging procedures, and enhance patient outcomes.

In this initiative, GEHC is likely to leverage its SIGNA MRI systems, which offer patient-specific imaging and enhanced workflows through AI integration. Additionally, the Edison AI platform enables real-time image analysis and data-driven insights, streamlining imaging operations.

The second focus area is advancing solutions for neurodegenerative diseases, a critical and growing global healthcare challenge. The Hub seeks to utilize advanced imaging technologies to better understand the complex functions of the brain and the progression of neurodegenerative conditions like Alzheimer's and Parkinson’s disease. By improving the accuracy of early diagnosis and developing targeted imaging techniques, this initiative aims to accelerate the development of effective treatments.

For neurodegenerative diseases, GEHC offers specialized imaging technologies like Discovery MI PET/CT and advanced MRI systems for brain health diagnostics. Products such as DaTscan help differentiate Parkinson’s from other disorders, while AI integration enhances the precise detection and monitoring of neurodegenerative conditions, improving research and patient outcomes.

The third pillar of the Hub’s mission is driving accessible precision oncology, particularly through innovative quantitative imaging methods. These methods are designed to monitor patient responses to radiopharmaceutical therapies in real-time, allowing for tailored treatment adjustments. This focus not only seeks to enhance treatment outcomes but also aims to standardize and democratize access to cutting-edge oncology diagnostics and therapies globally.

In precision oncology, GE HealthCare provides solutions like the Discovery NM/CT 870 for tumor imaging, cyclotrons for radiopharmaceutical production, and contrast agents with quantitative imaging software to track treatment responses, advancing access to cancer care and standardizing oncology practices.

GEHC’s Zacks Rank & Stocks to Consider

GEHC carries a Zacks Rank #4 (Sell) at present.

Some better-ranked stocks in the broader medical space are Masimo MASI, Accuray ARAY and Abbott Laboratories ABT.

Masimo, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 11.8% for 2025. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Its shares have risen 31.7% against the industry’s 1% decline in the past six months.

Accuray, carrying a Zacks Rank #2 at present, has an estimated growth rate of 1200% for 2025. Its earnings missed estimates in three of the trailing four quarters and met in one, delivering an average negative surprise of 141.97%.

ARAY’s shares have gained 8.8% against the industry’s 1% decline in the past six months.

Abbott, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 10% for 2025. It delivered a trailing four-quarter average earnings surprise of 1.64%.

ABT’s shares have risen 8.5% in the past six months compared with the industry’s 7.2% growth.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT) : Free Stock Analysis Report

Accuray Incorporated (ARAY) : Free Stock Analysis Report

Masimo Corporation (MASI) : Free Stock Analysis Report

GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research